CD79B limits response of diffuse large B cell lymphoma to ibrutinib

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Ibrutinib is a promising treatment for B-cell malignancies by blocking B cell receptor signaling.
• Primary or secondary resistance limits ibrutinib's clinical efficacy in many patients.
• Activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) exhibits variable responses to ibrutinib.

Purpose of the Study:

• To investigate the mechanisms of ibrutinib resistance in ABC-DLBCL.
• To identify potential biomarkers for predicting therapeutic response to ibrutinib.
• To explore combination therapies to overcome ibrutinib resistance.

Main Methods:

• cDNA microarray analysis to identify differentially expressed genes.
• Western blot analysis to assess protein expression and phosphorylation.
• Functional studies involving CD79B depletion and inhibition of AKT/MAPK pathways.

Main Results:

• CD79B was found to be upregulated in ibrutinib-resistant ABC-DLBCL.
• CD79B overexpression induced ibrutinib resistance and enhanced AKT/MAPK activation.
• CD79B depletion sensitized cells to ibrutinib and reduced AKT/MAPK phosphorylation.
• Combination therapy with AKT or MAPK inhibitors circumvented resistance.

Conclusions:

• CD79B overexpression activating AKT/MAPK is a key mechanism of ibrutinib resistance in ABC-DLBCL.
• CD79B serves as a potential biomarker for predicting ibrutinib treatment outcomes.
• Targeting CD79B or downstream signaling pathways offers a strategy to overcome ibrutinib resistance.